Literature DB >> 35695930

Blocking autophagy with chloroquine aggravates lipid accumulation and reduces intracellular energy synthesis in hepatocellular carcinoma cells, both contributing to its anti-proliferative effect.

Fengming Xu1,2, Hans-Michael Tautenhahn1,3, Olaf Dirsch4, Uta Dahmen5.   

Abstract

PURPOSE: The autophagy inhibitor chloroquine enhances the effect of targeted therapy using tyrosine kinase inhibitor in liver cancer. We would like to further understand the specific mechanism by which chloroquine inhibits the proliferation of tumor cells.
METHODS: We used a human hepatocarcinoma cell line (HepG2) as cell culture model. In contrast to the control groups (treated only with complete medium), cells in experimental groups were treated either with complete medium + 40 ng/ml Hepatocyte growth factor (HGF), or with complete medium + 60 μM chloroquine or with complete medium + 40 ng/ml HGF + 60 μM chloroquine for 24 h. Cell number and ATP content were investigated using spectrophotometric assays. Cell proliferation and apoptosis were detected by immunohistochemistry. Cell morphological alterations were examined by Giemsa and H&E staining. Cellular lipid content was determined by Oil Red O staining and Triglyceride quantification assay. Autophagy-related proteins (LC3B and p62) and hepatocyte proliferation-related protein (S6K1) were examined using western blot. The autophagic flux of cells was assessed by mRFP-EGFP-LC3 transfection assay.
RESULTS: We found that chloroquine inhibited the proliferation of HepG2 cells, as evidenced by a decrease in cellular ATP content, Ki-67 and S6K1 protein expression and a reduction in cell number. This finding was associated with an increase in lipid content. As expected, chloroquine inhibited autophagy of HepG2 cells, as evidenced by the accumulation of LC3B-II and the significant upregulation of p62. mRFP-EGFP-LC3 transfection assay showed that indeed chloroquine blocked the autophagic flux in HepG2 cells.
CONCLUSION: Chloroquine impaired proliferation of HepG2 cells might be due to intracellular accumulation of lipids and inhibition of energy synthesis.
© 2022. The Author(s).

Entities:  

Keywords:  Autophagy; Cancer; Chloroquine; Energy; Lipid; Liver

Year:  2022        PMID: 35695930      PMCID: PMC9587105          DOI: 10.1007/s00432-022-04074-2

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.322


  44 in total

Review 1.  Regulation of lipid stores and metabolism by lipophagy.

Authors:  K Liu; M J Czaja
Journal:  Cell Death Differ       Date:  2012-05-18       Impact factor: 15.828

2.  Liver autophagy contributes to the maintenance of blood glucose and amino acid levels.

Authors:  Junji Ezaki; Naomi Matsumoto; Mitsue Takeda-Ezaki; Masaaki Komatsu; Katsuyuki Takahashi; Yuka Hiraoka; Hikari Taka; Tsutomu Fujimura; Kenji Takehana; Mitsutaka Yoshida; Junichi Iwata; Isei Tanida; Norihiko Furuya; Dong-Mei Zheng; Norihiro Tada; Keiji Tanaka; Eiki Kominami; Takashi Ueno
Journal:  Autophagy       Date:  2011-07-01       Impact factor: 16.016

3.  Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients.

Authors:  Francesco Tovoli; Luca Ielasi; Andrea Casadei-Gardini; Alessandro Granito; Francesco Giuseppe Foschi; Giulia Rovesti; Giulia Negrini; Giulia Orsi; Matteo Renzulli; Fabio Piscaglia
Journal:  J Hepatol       Date:  2019-08-23       Impact factor: 25.083

4.  Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma.

Authors:  Satoshi Shimizu; Tetsuo Takehara; Hayato Hikita; Takahiro Kodama; Hinako Tsunematsu; Takuya Miyagi; Atsushi Hosui; Hisashi Ishida; Tomohide Tatsumi; Tatsuya Kanto; Naoki Hiramatsu; Naonobu Fujita; Tamotsu Yoshimori; Norio Hayashi
Journal:  Int J Cancer       Date:  2011-09-12       Impact factor: 7.396

Review 5.  Autophagy: cellular and molecular mechanisms.

Authors:  Danielle Glick; Sandra Barth; Kay F Macleod
Journal:  J Pathol       Date:  2010-05       Impact factor: 7.996

6.  Targeting autophagy enhances sorafenib lethality for hepatocellular carcinoma via ER stress-related apoptosis.

Authors:  Ying-Hong Shi; Zhen-Bin Ding; Jian Zhou; Bo Hui; Guo-Ming Shi; Ai-Wu Ke; Xiao-Ying Wang; Zhi Dai; Yuan-Fei Peng; Cheng-Yu Gu; Shuang-Jian Qiu; Jia Fan
Journal:  Autophagy       Date:  2011-10-01       Impact factor: 16.016

Review 7.  Regulation mechanisms and signaling pathways of autophagy.

Authors:  Congcong He; Daniel J Klionsky
Journal:  Annu Rev Genet       Date:  2009       Impact factor: 16.830

Review 8.  Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects.

Authors:  Jörg Thomas Hartmann; Michael Haap; Hans-Georg Kopp; Hans-Peter Lipp
Journal:  Curr Drug Metab       Date:  2009-06       Impact factor: 3.731

Review 9.  Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis.

Authors:  Shenhong Wu; John J Chen; Andrzej Kudelka; Janice Lu; Xiaolei Zhu
Journal:  Lancet Oncol       Date:  2008-01-24       Impact factor: 41.316

10.  The lysosomal inhibitor, chloroquine, increases cell surface BMPR-II levels and restores BMP9 signalling in endothelial cells harbouring BMPR-II mutations.

Authors:  Benjamin J Dunmore; Kylie M Drake; Paul D Upton; Mark R Toshner; Micheala A Aldred; Nicholas W Morrell
Journal:  Hum Mol Genet       Date:  2013-05-12       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.